Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to develop transformative medicines to improve the lives of patients with central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy and other diseases associated with dysregulation or overexpression of filamin A.
Partnerships Yale University: exclusive worldwide license (Feb 26, 2025) for simufilam in TSC-related epilepsy and other indications; TSC Alliance (TSCA)/TSC Preclinical Consortium: preclinical collaboration
Indications
TSC-related epilepsy(Preclinical)
Alzheimer’s disease(Phase 3)
Status note TSC-related epilepsy: IND filed for a proof-of-concept trial; FDA placed the proposed trial on full clinical hold Dec 15, 2025 (additional preclinical data and protocol changes requested); preclinical results in Tsc1-CKO mouse model announced Aug 2025. Alzheimer’s program discontinued: RETHINK-ALZ (Nov 25, 2024) and REFOCUS-ALZ (Mar 25, 2025) missed endpoints; program phase-out completed Q2 2025.
SavaDx
Stage not disclosed · Terminated
Status note Blood-based early-stage Alzheimer’s diagnostic; development discontinued mid-2025 for business, technical and personnel reasons.
Per-asset detail extracted from the 10-Q filed 2026-07-29. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.